Yoshida, Ryuichi - OU Author List - OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY

ID (desc)

Hepatitis C Virus-specific T-cell Response Correlates with Hepatitis Activity and Donor IL28B Genotype Early after Liver Transplantation

JaLCDOI	10.18926/AMO/52898
FullText URL	68_5_291.pdf
Author	Tsuzaki, Ryuichiro\| Takaki, Akinobu\| Yagi, Takahito\| Ikeda, Fusao\| Koike, Kazuko\| Iwasaki, Yoshiaki\| Shiraha, Hidenori\| Miyake, Yasuhiro\| Sadamori, Hiroshi\| Shinoura, Susumu\| Umeda, Yuzo\| Yoshida, Ryuichi\| Nobuoka, Daisuke\| Utsumi, Masashi\| Nakayama, Eiichi\| Fujiwara, Toshiyoshi\| Yamamoto, Kazuhide\|
Abstract	It is not known how the immune system targets hepatitis C virus (HCV)-infected HLA-mismatched hepatocytes under immune-suppressed conditions after orthotopic liver transplantation (OLT). In addition, the relationship between the HCV-specific immune response and IL28B variants as predictors of HCV clearance has not been well-characterized. We determined the IL28B polymorphisms for 57 post-OLT HCV carriers, and we assessed the HCV-specific immune responses by measuring the peripheral blood mononuclear cell-derived HCV-specific interferon-gamma (IFN-γ) response using an enzyme-linked immunospot assay. At 1-3 years after OLT, patients with no active hepatitis showed higher total spots on the immunospot assay. At＞3 years after OLT, patients with resolved HCV showed higher levels of core, NS3, NS5A, and total spots compared to the chronic hepatitis patients. The IL28B major genotype in the donors correlated with higher spot counts for NS5A and NS5B proteins at 1-3 years after OLT. In the post-OLT setting, the HCV-specific immune response could be strongly induced in patients with no active hepatitis with an IL28B major donor or sustained virological response. Strong immune responses in the patients with no active hepatitis could only be maintained for 3 years and diminished later. It may be beneficial to administer IFN treatment starting 3 years after OLT, to induce the maximum immunological effect.
Keywords	interferon gamma ELISPOT assay single nucleotide polymorphisms dendritic cell CD4 T cell
Amo Type	Original Article
Publication Title	Acta Medica Okayama
Published Date	2014-10
Volume	volume68
Issue	issue5
Publisher	Okayama University Medical School
Start Page	291
End Page	302
ISSN	0386-300X
NCID	AA00508441
Content Type	Journal Article
language	English
Copyright Holders	CopyrightⒸ 2014 by Okayama University Medical School
File Version	publisher
Refereed	True
PubMed ID	25338486
Web of Science KeyUT	000343269300006
Related Url	http://ousar.lib.okayama-u.ac.jp/metadata/53129

Living Donor Liver Transplantation to a Survivor of LiverResection for Hepatocellular Carcinoma with Major Portal Vein Invasion

JaLCDOI	10.18926/AMO/49671
FullText URL	67_2_117.pdf
Author	Sadamori, Hiroshi\| Yagi, Takahito\| Shinoura, Susumu\| Umeda, Yuzo\| Yoshida, Ryuichi\| Sato, Daisuke\| Nobuoka, Daisuke\| Utsumi, Masashi\| Fujiwara, Toshiyoshi\|
Abstract	We present a case of living donor liver transplantation to a 3-year disease-free survivor of liver resection for hepatocellular carcinoma (HCC) with major portal vein invasion. A 48-year-old man had HCC in the right lobe with a portal venous tumor thrombus extending into the left portal vein. An extended right lobectomy with thrombectomy was performed to remove the thrombus. Three years after liver resection, the patient experienced liver failure, with massive ascites and jaundice due to the formation of a thrombus in the main and left portal veins. During the 3 years after liver resection, no metastasis or recurrence of HCC had been detected, and tumor markers had been within normal ranges. The portal venous thrombus did not show any arterial enhancement under contrast-enhanced computed tomography, suggesting that the co-existence of any HCC component in the portal venous thrombus may have been negative. Based on these findings, living donor liver transplantation was performed using a right lobe graft from the patientʼs son. The patient is alive at 87 months after the transplantation, with no evidence of HCC recurrence.
Keywords	living donor liver transplantation hepatocellular carcinoma portal vein invasion liver resection
Amo Type	Case Report
Publication Title	Acta Medica Okayama
Published Date	2013-04
Volume	volume67
Issue	issue2
Publisher	Okayama University Medical School
Start Page	117
End Page	121
ISSN	0386-300X
NCID	AA00508441
Content Type	Journal Article
language	English
Copyright Holders	CopyrightⒸ 2013 by Okayama University Medical School
File Version	publisher
Refereed	True
PubMed ID	23603929
Web of Science KeyUT	000317801700007